Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes a next-generation ROS1 inhibitor, a brain-penetrant IDH1 inhibitor, and an innovative drug-drug conjugate (DDC) program. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai.
| Website | http://www.nuvationbio.com |
| Revenue | $7.9 million |
| Employees | 234 (177 on RocketReach) |
| Founded | 2018 |
| Address | 1500 Broadway STE: 1401, New York, New York 10036, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+26 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Pharmaceutical, Drug Discovery, Health Care, Biotechnology |
| Keywords | Global Biopharma, Oncology Therapeutics, Cancer Treatment, Oncology Research, Biopharmaceutical Development, Drug Discovery, Novel Therapies, New Drug Development, Clinical Trials, Targeted Therapy, Pharmaceutical Innovation, Cancer Research, Pharmaceutical Research, Precision Medicine, Therapeutic Candidates, Unmet Medical Needs, Biotechnology, Drug Development |
| Competitors | Amgen, Bristol Myers Squibb, AstraZeneca, Novartis, Gilead Sciences, Vertex Pharmaceuticals, Genentech, Regeneron, Moderna Therapeutics, Lilly India +39 more (view full list) |
Looking for a particular Nuvation Bio employee's phone or email?
The Nuvation Bio annual revenue was $7.9 million in 2026.
David Hung is the Founder, President and CEO of Nuvation Bio.
177 people are employed at Nuvation Bio.
Nuvation Bio is based in New York, New York.